Chiron Capital Management’s AbbVie ABBV Stock Holding History

Chiron Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,942	Closed	-$170K	–	83
2020 Q3	$170K	Buy	+1,942	New	+$183K	0.14%	78

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Chiron Capital Management's ABBV Position: Q4 2020 in Review

Chiron Capital Management sold out of AbbVie (ABBV) in Q4 2020, closing a stake of 1,942 shares — an estimated $170K sold.

Chiron Capital Management first reported a position in ABBV in Q3 2020 and held it in 1 quarter. The position peaked at $170K in Q3 2020. 2,598 funds tracked by Wall St. Rank hold ABBV as of Q4 2020.

Chiron Capital Management reported no remaining AbbVie position as of Q4 2020 after selling out during the quarter.
Chiron Capital Management sold 1,942 AbbVie shares in Q4 2020, an estimated $170K.
Chiron Capital Management first reported a position in AbbVie in Q3 2020 and held it in 1 quarter.
Chiron Capital Management's AbbVie position peaked at $170K in Q3 2020.
2,598 funds tracked by Wall St. Rank held AbbVie as of Q4 2020.

Based on Chiron Capital Management's 13F filing for Q4 2020, filed 5 Mar 2021.